Loading...

Integra LifeSciences Holdings

DB:IL3
Snowflake Description

Moderate growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IL3
DB
$5B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
IL3 Share Price and Events
7 Day Returns
-0.4%
DB:IL3
2.4%
DE Medical Equipment
0.7%
DE Market
1 Year Returns
6.7%
DB:IL3
18.1%
DE Medical Equipment
-8.7%
DE Market
IL3 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Integra LifeSciences Holdings (IL3) -0.4% 8.9% 23.8% 6.7% 69.6% 199%
DE Medical Equipment 2.4% 5.1% 10.3% 18.1% 82.1% 188.6%
DE Market 0.7% 2.2% 8.8% -8.7% 7.6% 9.7%
1 Year Return vs Industry and Market
  • IL3 underperformed the Medical Equipment industry which returned 18.1% over the past year.
  • IL3 outperformed the Market in Germany which returned -8.7% over the past year.
Price Volatility
IL3
Industry
5yr Volatility vs Market

Value

 Is Integra LifeSciences Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Integra LifeSciences Holdings to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Integra LifeSciences Holdings.

DB:IL3 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 16 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:IL3
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.933 (1 + (1- 21%) (28.42%))
1.095
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.1
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.095 * 5.96%)
6.75%

Discounted Cash Flow Calculation for DB:IL3 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Integra LifeSciences Holdings is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:IL3 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.75%)
2019 199.43 Analyst x4 186.81
2020 255.49 Analyst x3 224.18
2021 307.38 Analyst x3 252.65
2022 336.20 Analyst x1 258.85
2023 357.52 Est @ 6.34% 257.85
2024 373.64 Est @ 4.51% 252.42
2025 385.68 Est @ 3.22% 244.08
2026 394.65 Est @ 2.33% 233.95
2027 401.34 Est @ 1.7% 222.86
2028 406.38 Est @ 1.26% 211.38
Present value of next 10 years cash flows $2,345.04
DB:IL3 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $406.38 × (1 + 0.23%) ÷ (6.75% – 0.23%)
$6,240.80
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $6,240.80 ÷ (1 + 6.75%)10
$3,246.21
DB:IL3 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,345.04 + $3,246.21
$5,591.24
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $5,591.24 / 85.23
$65.6
DB:IL3 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:IL3 represents 0.87103x of NasdaqGS:IART
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87103x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 65.60 x 0.87103
€57.14
Value per share (EUR) From above. €57.14
Current discount Discount to share price of €49.03
= -1 x (€49.03 - €57.14) / €57.14
14.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Integra LifeSciences Holdings is available for.
Intrinsic value
14%
Share price is €49.03 vs Future cash flow value of €57.14
Current Discount Checks
For Integra LifeSciences Holdings to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Integra LifeSciences Holdings's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Integra LifeSciences Holdings's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Integra LifeSciences Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Integra LifeSciences Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:IL3 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.73
NasdaqGS:IART Share Price ** NasdaqGS (2019-03-21) in USD $56.29
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 31.93x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 18.55x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Integra LifeSciences Holdings.

DB:IL3 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:IART Share Price ÷ EPS (both in USD)

= 56.29 ÷ 0.73

76.71x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Integra LifeSciences Holdings is overvalued based on earnings compared to the DE Medical Equipment industry average.
  • Integra LifeSciences Holdings is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Integra LifeSciences Holdings's expected growth come at a high price?
Raw Data
DB:IL3 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 76.71x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts
35.4%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.86x
Germany Market PEG Ratio Median Figure of 275 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

DB:IL3 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 76.71x ÷ 35.4%

2.17x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Integra LifeSciences Holdings is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Integra LifeSciences Holdings's assets?
Raw Data
DB:IL3 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $16.15
NasdaqGS:IART Share Price * NasdaqGS (2019-03-21) in USD $56.29
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.33x
Germany Market PB Ratio Median Figure of 571 Publicly-Listed Companies 1.79x
DB:IL3 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:IART Share Price ÷ Book Value per Share (both in USD)

= 56.29 ÷ 16.15

3.48x

* Primary Listing of Integra LifeSciences Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Integra LifeSciences Holdings is good value based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Integra LifeSciences Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Integra LifeSciences Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Integra LifeSciences Holdings expected to perform in the next 1 to 3 years based on estimates from 16 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
35.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Integra LifeSciences Holdings expected to grow at an attractive rate?
  • Integra LifeSciences Holdings's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Integra LifeSciences Holdings's earnings growth is expected to exceed the Germany market average.
  • Integra LifeSciences Holdings's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:IL3 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:IL3 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts 35.4%
DB:IL3 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 16 Analysts 4.6%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 11.9%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 5.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:IL3 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:IL3 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 1,785 397 3
2021-12-31 1,678 352 200 8
2020-12-31 1,598 300 172 14
2019-12-31 1,522 245 126 16
DB:IL3 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1,472 200 61
2018-09-30 1,458 169 80
2018-06-30 1,371 135 70
2018-03-31 1,287 127 69
2017-12-31 1,188 115 65
2017-09-30 1,075 110 49
2017-06-30 1,047 111 66
2017-03-31 1,014 120 68
2016-12-31 992 116 75
2016-09-30 985 136 61
2016-06-30 958 108 9
2016-03-31 919 98 9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Integra LifeSciences Holdings's earnings are expected to grow significantly at over 20% yearly.
  • Integra LifeSciences Holdings's revenue is expected to grow by 4.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:IL3 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below

All data from Integra LifeSciences Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IL3 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 3.04 3.04 3.04 1.00
2021-12-31 2.41 2.65 2.21 3.00
2020-12-31 2.03 2.34 1.79 5.00
2019-12-31 1.45 1.63 1.36 6.00
DB:IL3 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.73
2018-09-30 0.99
2018-06-30 0.88
2018-03-31 0.89
2017-12-31 0.84
2017-09-30 0.64
2017-06-30 0.87
2017-03-31 0.91
2016-12-31 1.00
2016-09-30 0.83
2016-06-30 0.13
2016-03-31 0.12

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Integra LifeSciences Holdings is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Integra LifeSciences Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Integra LifeSciences Holdings has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Integra LifeSciences Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Integra LifeSciences Holdings's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Integra LifeSciences Holdings has delivered over 20% year on year earnings growth in the past 5 years.
  • Integra LifeSciences Holdings's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Integra LifeSciences Holdings's 1-year earnings growth is negative, it can't be compared to the DE Medical Equipment industry average.
Earnings and Revenue History
Integra LifeSciences Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Integra LifeSciences Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IL3 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1,472.44 60.80 600.40 78.04
2018-09-30 1,457.73 80.02 602.46 74.92
2018-06-30 1,370.71 69.88 572.60 69.65
2018-03-31 1,286.68 69.34 545.95 66.29
2017-12-31 1,188.24 64.74 520.30 63.46
2017-09-30 1,075.30 48.64 474.55 60.18
2017-06-30 1,046.80 65.62 460.17 60.07
2017-03-31 1,013.94 67.54 445.05 59.00
2016-12-31 992.08 74.56 430.98 57.96
2016-09-30 984.57 61.30 426.06 56.96
2016-06-30 958.11 9.27 415.10 55.97
2016-03-31 919.17 8.54 395.20 53.31
2015-12-31 882.73 6.85 377.00 49.94
2015-09-30 853.65 12.28 359.57 47.04
2015-06-30 827.30 53.15 346.30 44.24
2015-03-31 781.99 45.82 325.10 41.57
2014-12-31 796.72 36.30 335.19 43.06
2014-09-30 798.41 29.66 344.98 46.59
2014-06-30 814.14 -9.66 355.96 48.51
2014-03-31 854.62 -12.83 380.41 50.97
2013-12-31 696.83 22.03 305.40 41.65
2013-09-30 829.88 -22.05 373.30 50.44
2013-06-30 826.72 21.49 364.68 50.49
2013-03-31 831.34 28.48 360.72 51.82
2012-12-31 830.87 41.20 349.45 51.01
2012-09-30 819.96 32.98 342.56 51.18
2012-06-30 812.06 31.01 337.50 51.26
2012-03-31 795.22 23.20 327.64 50.84

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Integra LifeSciences Holdings has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Integra LifeSciences Holdings used its assets less efficiently than the DE Medical Equipment industry average last year based on Return on Assets.
  • Integra LifeSciences Holdings's use of capital has not improved over the past 3 years (Return on Capital Employed).
X
Past performance checks
We assess Integra LifeSciences Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Integra LifeSciences Holdings has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Integra LifeSciences Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Integra LifeSciences Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Integra LifeSciences Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Integra LifeSciences Holdings's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Integra LifeSciences Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Integra LifeSciences Holdings Company Filings, last reported 2 months ago.

DB:IL3 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,375.80 1,363.60 143.49
2018-09-30 1,365.08 1,432.25 212.67
2018-06-30 1,341.91 1,476.49 188.59
2018-03-31 998.44 1,832.48 192.39
2017-12-31 962.31 1,844.56 176.46
2017-09-30 913.12 1,172.57 482.77
2017-06-30 894.56 881.02 155.26
2017-03-31 852.49 855.18 136.04
2016-12-31 839.67 665.00 102.30
2016-09-30 823.43 687.77 107.60
2016-06-30 794.79 706.14 86.80
2016-03-31 776.39 730.00 77.09
2015-12-31 751.44 714.49 48.13
2015-09-30 730.10 729.73 79.31
2015-06-30 711.72 654.30 131.30
2015-03-31 688.10 617.58 79.87
2014-12-31 704.32 630.89 71.73
2014-09-30 685.98 624.26 140.23
2014-06-30 689.23 632.68 137.16
2014-03-31 679.20 631.10 129.04
2013-12-31 666.09 394.50 120.61
2013-09-30 499.48 547.95 118.87
2013-06-30 516.59 546.28 98.64
2013-03-31 509.89 525.03 89.69
2012-12-31 517.78 523.67 96.94
2012-09-30 526.70 522.38 125.72
2012-06-30 507.21 520.32 114.79
2012-03-31 508.45 527.11 112.42
  • Integra LifeSciences Holdings's level of debt (99.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (59.6% vs 99.1% today).
  • Debt is not well covered by operating cash flow (14.6%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 3.8x coverage).
X
Financial health checks
We assess Integra LifeSciences Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Integra LifeSciences Holdings has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Integra LifeSciences Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Integra LifeSciences Holdings dividends. Estimated to be 0% next year.
If you bought €2,000 of Integra LifeSciences Holdings shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Integra LifeSciences Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Integra LifeSciences Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:IL3 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:IL3 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Integra LifeSciences Holdings has not reported any payouts.
  • Unable to verify if Integra LifeSciences Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Integra LifeSciences Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Integra LifeSciences Holdings has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Integra LifeSciences Holdings's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Integra LifeSciences Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Integra LifeSciences Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Integra LifeSciences Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Integra LifeSciences Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Pete Arduini
COMPENSATION $7,134,568
AGE 53
TENURE AS CEO 7.2 years
CEO Bio

Mr. Peter J. Arduini, also known as Pete, has been Chief Executive Officer and President at Derma Sciences, Inc. since February 2017. Mr. Arduini has been the Chief Executive Officer of Integra LifeSciences Holdings Corporation since January 3, 2012 and has been its President since November 1, 2010. Mr. Arduini serves as the Chief Executive Officer and President of Integra Lifesciences Corporation. He served as the Chief Operating Officer of Integra LifeSciences Holdings Corporation from November 1, 2010 to January 3, 2012. Before joining Integra, he served as Corporate Vice President and President of Medication Delivery Business at Baxter Healthcare Corporation from 2005 to 2010. He served as the President of Medication Delivery Business of Baxter International Inc. and Baxter World Trade Corporation (subsidiaries of Baxter International, Inc.) from April 2005 to October 29, 2010. He served as Corporate Vice President at Baxter International Inc. from April 2005 to October 2010. Prior to joining Baxter, he served on General Electric Healthcare, where he spent much of his 15 years in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business. Along with having served in sales management, He also has overseen marketing, market research, product design and engineering program development for its radiology & cardiology franchise. He served as the Global General Manager of General Electric Healthcares’ Cat Scan (CT) and functional imaging business. He also served as General Manager of USA Sales, for GE’s diagnostic imaging business. Prior to joining GE, He spent four years with Procter and Gamble. He serves as a Director of Bristol-Myers Squibb Farmacêutica Portuguesa, SA. He has been a Director of Derma Sciences, Inc. since February 2017. He has been a Director of Integra LifeSciences Holdings Corporation since January 2012. He has been an Independent Director of Bristol-Myers Squibb Company since April 01, 2016. Mr. Arduini also serves on the Board of Directors of ADVAMED (the Advanced Medical Technology Association), the Board of Directors of MDIC (the Medical Device Innovation Consortium), and the Board of Directors of the National Italian American Foundation. He also serves on the Board of Trustees of Susquehanna University. He served as a Director of SeaSpine Holdings Corporation until July 01, 2015. Mr. Arduini received his Master’s in Business Administration Degree from Northwestern University’s Kellogg Graduate School of Management, after graduating from Susquehanna University with a Bachelor of Science degree in Marketing.

CEO Compensation
  • Pete's compensation has been consistent with company performance over the past year.
  • Pete's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Integra LifeSciences Holdings management team in years:

6.3
Average Tenure
57
Average Age
  • The average tenure for the Integra LifeSciences Holdings management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Pete Arduini

TITLE
President
COMPENSATION
$7M
AGE
53
TENURE
7.2 yrs

Richard Caruso

TITLE
Founder and Chairman Emeritus
COMPENSATION
$38K
AGE
75
TENURE
30.2 yrs

Glenn Coleman

TITLE
Corporate VP of International & CFO
COMPENSATION
$2M
AGE
50
TENURE
4.8 yrs

Dan Reuvers

TITLE
Corporate VP and President of Specialty Surgical Solutions
COMPENSATION
$1M
AGE
55
TENURE
6.3 yrs

Bob Davis

TITLE
Corporate VP and President of Orthopedics & Tissue Technologies
COMPENSATION
$1M
AGE
59
TENURE
6.3 yrs

John Mooradian

TITLE
Corporate Vice President of Global Operations & Supply Chain
COMPENSATION
$756K
AGE
62
TENURE
6.3 yrs

Jeffrey Mosebrook

TITLE
VP, Principal Accounting Officer
AGE
42
TENURE
1.4 yrs

Ken Burhop

TITLE
Corporate VP & Chief Scientific Officer
AGE
64
TENURE
5.1 yrs

William Compton

TITLE
Chief Information Officer & Senior VP

Sravan Emany

TITLE
Senior Vice President of Strategy
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure and age of the Integra LifeSciences Holdings board of directors in years:

6.6
Average Tenure
60.5
Average Age
  • The tenure for the Integra LifeSciences Holdings board of directors is about average.
Board of Directors

Stuart Essig

TITLE
Chairman
COMPENSATION
$370K
AGE
56
TENURE
7.2 yrs

Pete Arduini

TITLE
President
COMPENSATION
$7M
AGE
53
TENURE
7.2 yrs

Richard Caruso

TITLE
Founder and Chairman Emeritus
COMPENSATION
$38K
AGE
75
TENURE
1.8 yrs

Chris Schade

TITLE
Director
COMPENSATION
$260K
AGE
57
TENURE
13.2 yrs

Ray Murphy

TITLE
Director
COMPENSATION
$260K
AGE
70
TENURE
9.9 yrs

Barbara Hill

TITLE
Presiding Director
COMPENSATION
$245K
AGE
66
TENURE
0.5 yrs

Donald Morel

TITLE
Director
COMPENSATION
$245K
AGE
60
TENURE
5.6 yrs

Keith N. Bradley

TITLE
Director
COMPENSATION
$260K
AGE
73
TENURE
27.2 yrs

Lloyd Howell

TITLE
Director
COMPENSATION
$245K
AGE
51
TENURE
6 yrs

Rhonda Ballintyn

TITLE
Director
AGE
61
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Integra LifeSciences Holdings insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Mar 19 Buy Rhonda Germany Ballintyn Individual 14. Mar 19 14. Mar 19 1,933 €49.62 €95,912
18. Mar 19 Sell Lisa Evoli Individual 15. Mar 19 15. Mar 19 -1,291 €49.37 €-63,738
06. Nov 18 Buy Barbara Hill Individual 05. Nov 18 05. Nov 18 3,705 €47.27 €175,122
18. Oct 18 Sell Provco Leasing Corporation Company 16. Oct 18 17. Oct 18 -46,676 €54.79 €-2,556,054
10. Aug 18 Sell Jeffrey Mosebrook Individual 10. Aug 18 10. Aug 18 -1,000 €54.67 €-54,671
10. Aug 18 Sell Lisa Evoli Individual 09. Aug 18 09. Aug 18 -4,432 €54.53 €-241,686
10. Aug 18 Sell Glenn Coleman Individual 09. Aug 18 09. Aug 18 -8,916 €54.45 €-485,445
X
Management checks
We assess Integra LifeSciences Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Integra LifeSciences Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, Asia Pacific, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.

Details
Name: Integra LifeSciences Holdings Corporation
IL3
Exchange: DB
Founded: 1989
$4,228,555,838
85,229,075
Website: http://www.integralife.com
Address: Integra LifeSciences Holdings Corporation
311 Enterprise Drive,
Plainsboro,
New Jersey, 08536,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS IART Common Stock Nasdaq Global Select US USD 16. Aug 1995
DB IL3 Common Stock Deutsche Boerse AG DE EUR 16. Aug 1995
Number of employees
Current staff
Staff numbers
4,500
Integra LifeSciences Holdings employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/21 20:41
End of day share price update: 2019/03/21 00:00
Last estimates confirmation: 2019/03/18
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.